JP2023550043A5 - - Google Patents
Info
- Publication number
- JP2023550043A5 JP2023550043A5 JP2023528206A JP2023528206A JP2023550043A5 JP 2023550043 A5 JP2023550043 A5 JP 2023550043A5 JP 2023528206 A JP2023528206 A JP 2023528206A JP 2023528206 A JP2023528206 A JP 2023528206A JP 2023550043 A5 JP2023550043 A5 JP 2023550043A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- axl
- composition according
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113040P | 2020-11-12 | 2020-11-12 | |
| US63/113,040 | 2020-11-12 | ||
| PCT/US2021/058747 WO2022103811A1 (en) | 2020-11-12 | 2021-11-10 | Methods of treating axl-expressing cancers with anti-axl antibodies, antibody fragments and their immunoconjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550043A JP2023550043A (ja) | 2023-11-30 |
| JP2023550043A5 true JP2023550043A5 (https=) | 2024-11-12 |
Family
ID=81601645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528206A Pending JP2023550043A (ja) | 2020-11-12 | 2021-11-10 | 抗Ａｘｌ抗体、抗体断片およびそれらの免疫コンジュゲートを用いたＡｘｌ発現癌の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250276075A1 (https=) |
| EP (1) | EP4243877A4 (https=) |
| JP (1) | JP2023550043A (https=) |
| KR (1) | KR20230107615A (https=) |
| CN (1) | CN116635053A (https=) |
| AU (1) | AU2021377224A1 (https=) |
| CA (1) | CA3197822A1 (https=) |
| IL (1) | IL302589A (https=) |
| MX (1) | MX2023005571A (https=) |
| TW (1) | TW202227484A (https=) |
| WO (1) | WO2022103811A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025198961A1 (en) * | 2024-03-19 | 2025-09-25 | BioAtla, Inc | Methods and pharmaceutical composition for the treatment of adenoid cystic carcinoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102549016B (zh) * | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| RU2577986C2 (ru) * | 2010-06-18 | 2016-03-20 | Дженентек, Инк. | Антитела против axl и способы их применения |
| DK4074735T3 (da) * | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| SMT202600033T1 (it) * | 2016-04-15 | 2026-03-09 | Bioatla Inc | Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi |
| AU2017320874B2 (en) * | 2016-08-31 | 2024-03-07 | Bioatla, Llc | Conditionally active polypeptides and methods of generating them |
| SG11202002331QA (en) * | 2017-09-13 | 2020-04-29 | Nat Res Council Canada | Axl-specific antibodies and uses thereof |
-
2021
- 2021-11-10 CN CN202180076413.6A patent/CN116635053A/zh active Pending
- 2021-11-10 JP JP2023528206A patent/JP2023550043A/ja active Pending
- 2021-11-10 KR KR1020237019246A patent/KR20230107615A/ko active Pending
- 2021-11-10 WO PCT/US2021/058747 patent/WO2022103811A1/en not_active Ceased
- 2021-11-10 US US18/252,542 patent/US20250276075A1/en active Pending
- 2021-11-10 IL IL302589A patent/IL302589A/en unknown
- 2021-11-10 AU AU2021377224A patent/AU2021377224A1/en active Pending
- 2021-11-10 EP EP21892705.1A patent/EP4243877A4/en active Pending
- 2021-11-10 MX MX2023005571A patent/MX2023005571A/es unknown
- 2021-11-10 CA CA3197822A patent/CA3197822A1/en active Pending
- 2021-11-12 TW TW110142136A patent/TW202227484A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamaguchi et al. | Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer | |
| JP2007515469A5 (https=) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| KR20240004657A (ko) | 종양 질환의 치료에서의 의약의 용도 | |
| US20090285841A1 (en) | Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof | |
| EP2254570B1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| CN109498627A (zh) | 一种治疗肿瘤的药物组合物及其应用 | |
| ES2330324T3 (es) | Derivados del epotilon para el tratamiento del hepatoma y de otros canceres. | |
| WO2024183645A1 (zh) | 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 | |
| CN108524533A (zh) | 一种化合物用作抗肿瘤药物增效剂和逆转剂 | |
| KR20240012592A (ko) | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 | |
| JP2023550043A5 (https=) | ||
| TW202110448A (zh) | Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| RU2657604C2 (ru) | Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| Ogawa | A recent overview of chemotherapy for advanced stomach cancer in Japan | |
| RU2179452C1 (ru) | Способ лечения злокачественных новообразований и комплексный препарат, обладающий противоопухолевым действием, для осуществления способа | |
| US20210315898A1 (en) | Combination therapy for treating cancer | |
| CN107519171A (zh) | 洛匹那韦减轻伊立替康毒性的医药新用途 | |
| CN111388665B (zh) | 一种治疗肿瘤的复合物及其制剂和用途 | |
| CN119326894A (zh) | Gsdme抑制剂用于制造预防和治疗化疗时外周神经损伤的药物的用途 | |
| CN121550252A (zh) | 双二羧酸二氨络铂抗癌药物 |